Atlas Venture Associates IX, L.P. 4
4 · Unum Therapeutics Inc. · Filed Apr 3, 2018
Insider Transaction Report
Form 4
Atlas Venture Fund IX, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2018-04-03+83,037→ 3,267,483 total - Conversion
Common Stock
2018-04-03+3,184,446→ 3,184,446 total - Purchase
Common Stock
2018-04-03$12.00/sh+94,052$1,128,624→ 3,361,535 total - Conversion
Series A Preferred Stock
2018-04-03−3,184,446→ 0 total→ Common Stock (3,184,446 underlying) - Conversion
Series B Preferred Stock
2018-04-03−83,037→ 0 total→ Common Stock (83,037 underlying)
Footnotes (2)
- [F1]Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein, if any.